CD70 and glioblastoma: Jin et al. [62] demonstrated that targeting CD70Pos glioblastoma cells with chimeric antigen receptor T cells (CAR T-cells) triggered a strong antitumor response, suggesting that CD70 is likely an optimal tumor immunotherapeutic target in GBM.